These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 19509260)

  • 1. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.
    Miranda TB; Cortez CC; Yoo CB; Liang G; Abe M; Kelly TK; Marquez VE; Jones PA
    Mol Cancer Ther; 2009 Jun; 8(6):1579-88. PubMed ID: 19509260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
    Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
    Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
    Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
    Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
    Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y
    Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells.
    Murata T; Kondo Y; Sugimoto A; Kawashima D; Saito S; Isomura H; Kanda T; Tsurumi T
    J Virol; 2012 May; 86(9):4752-61. PubMed ID: 22357272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
    Lee JK; Kim KC
    Biochem Biophys Res Commun; 2013 Sep; 438(4):647-52. PubMed ID: 23933322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
    Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
    Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells.
    Choudhury SR; Balasubramanian S; Chew YC; Han B; Marquez VE; Eckert RL
    Carcinogenesis; 2011 Oct; 32(10):1525-32. PubMed ID: 21798853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation.
    Momparler RL; Côté S; Momparler LF; Idaghdour Y
    Clin Epigenetics; 2014; 6(1):19. PubMed ID: 25313314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation.
    Momparler RL; Idaghdour Y; Marquez VE; Momparler LF
    Leuk Res; 2012 Aug; 36(8):1049-54. PubMed ID: 22472464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
    Meng CF; Zhu XJ; Peng G; Dai DQ
    Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
    Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP
    Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
    Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
    Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of DNA and Histone Methylation by 5-Aza-2'-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells.
    Momparler RL; Côté S; Momparler LF; Idaghdour Y
    Front Oncol; 2017; 7():19. PubMed ID: 28261562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML.
    Paul TA; Bies J; Small D; Wolff L
    Blood; 2010 Apr; 115(15):3098-108. PubMed ID: 20190193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
    Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
    Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
    Kawamoto K; Hirata H; Kikuno N; Tanaka Y; Nakagawa M; Dahiya R
    Int J Cancer; 2008 Aug; 123(3):535-42. PubMed ID: 18404682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.